1.72

1.15% -0.02

After Hours: 1.72

Fortress Biotech Inc (FBIO)

Overview News Price History Option Chain Financials Why FBIO Down? Discussions Forecast Stock Split

Fortress Biotech Inc stock is traded at $1.72, with a volume of 457.83K. It is down -1.15% in the last 24 hours and up +9.55% over the past month. Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.

Previous Close:

$1.74

Open:

$1.73

24h Volume:

457.83K

Relative Volume:

0.63

Market Cap:

$47.48M

Revenue:

$80.97M

Net Income/Loss:

$-78.31M

P/E Ratio:

-0.1158

EPS:

-14.85

Net Cash Flow:

$-129.56M

1W Performance:

-11.34%

1M Performance:

+9.55%

6M Performance:

+0.58%

1Y Performance:

-27.12%

1-Day Range:

$1.72

$1.81

1-Week Range:

$1.72

$1.99

52-Week Range:

$1.355

$4.43

Fortress Biotech Inc Stock (FBIO) Company Profile

Name

Fortress Biotech Inc

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

781-652-4500

Address

1111 KANE CONCOURSE, BAY HARBOR ISLANDS, NY

Employee

186

Twitter

@fortressbio

Next Earnings Date

2024-11-12

Latest SEC Filings

FBIO's Discussions on Twitter

Compare FBIO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FBIO Fortress Biotech Inc	1.72	47.48M	80.97M	-78.31M	-129.56M	-11.08
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Fortress Biotech Inc Stock (FBIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-15-24	Resumed	ROTH MKM	Buy
Aug-04-22	Initiated	Ladenburg Thalmann	Buy
Oct-02-20	Initiated	The Benchmark Company	Buy
Dec-18-19	Initiated	B. Riley FBR	Buy
Feb-28-18	Initiated	B. Riley FBR, Inc.	Buy
Jul-11-17	Initiated	Rodman & Renshaw	Buy
Mar-22-17	Initiated	JMP Securities	Mkt Outperform
Oct-03-16	Initiated	ROTH Capital	Buy

View All

Fortress Biotech Inc Stock (FBIO) Latest News

Dec 17, 2024

Fortress Biotech subsidiary gains FDA approval for cSCC therapy - Investing.com

Dec 17, 2024

Fortress Biotech subsidiary gains FDA approval for cSCC therapy By Investing.com - Investing.com UK

Dec 17, 2024

Dec 14, 2024

Objective long/short (FBIOP) Report - Stock Traders Daily

Dec 14, 2024

Dec 13, 2024

Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) - GlobeNewswire

Dec 13, 2024

Checkpoint Therapeutics Secures First FDA Approval for Novel Cancer Drug UNLOXCYT in $1B+ Market - StockTitan

Dec 13, 2024

Dec 04, 2024

Fortress Biotech (FRA:CNB1) EV-to-Revenue : 0.52 (As of Dec. 04, 2024) - GuruFocus.com

Dec 04, 2024

Dec 01, 2024

Fortress Biotech (STU:CNB1) Dividend Payout Ratio : 0.00 (As of Sep. 2024) - GuruFocus.com

Dec 01, 2024

Nov 30, 2024

Fortress Biotech (STU:CNB1) 3-Year Dividend Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com

Nov 30, 2024

Nov 26, 2024

Fortress Biotech, Inc. (NASDAQ:FBIO) Shares Sold by GSA Capital Partners LLP - Defense World

Nov 26, 2024

Nov 23, 2024

FBIOP.PFD (Fortress Biotech) Earnings Yield % : N/A% (As of Nov. 23, 2024) - GuruFocus.com

Nov 23, 2024

Nov 22, 2024

(FBIOP) Trading Signals - Stock Traders Daily

Nov 22, 2024

Fortress Biotech (FRA:CNB0.PFD) Total Liabilities : €125.98 Mil (As of Sep. 2024) - GuruFocus.com

Nov 22, 2024

Nov 21, 2024

Certain Restricted Stock Units of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 22-NOV-2024. - Marketscreener.com

Nov 21, 2024

Certain Warrants of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 22-NOV-2024. - Marketscreener.com

Nov 21, 2024

Fortress Biotech (FRA:CNB1) Capex-to-Operating-Cash-Flow : 0.00 (As of Sep. 2024) - GuruFocus.com

Nov 21, 2024

Nov 19, 2024

Fortress Biotech price target raised to $15 from $13 at Roth MKM - TipRanks

Nov 19, 2024

Nov 18, 2024

Fortress Biotech price target lowered to $4 from $5 at Alliance Global Partners - TipRanks

Nov 18, 2024

Fortress Biotech price target raised to $26 from $24 at H.C. Wainwright - TipRanks

Nov 18, 2024

Fortress Biotech (FRA:CNB1) Total Inventories : €9.00 Mil (As of Jun. 2024) - GuruFocus.com

Nov 18, 2024

Nov 17, 2024

Fortress Biotech Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance

Nov 17, 2024

Nov 15, 2024

Fortress Biotech: Q3 Earnings Snapshot - mySA

Nov 15, 2024